CD4 Expression Decrease by Antisense Oligonucleotides: Inhibition of Rat T CD4+ Cell Reactivity

Oligonucleotides

Volumn 13, Issue 4, 2003, Pages 217-228

  Rabanal, Manel ^a,b   Franch, Ángels ^a,b   Noé, Véronique ^a,b   Pelegrí, Carme ^a,b   Ciudad, Carlos J ^a,b   Castellote, Cristina ^a,b   Castell, Margarida ^a,b  

^a University of Barcelona ^*

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD4 ANTIGEN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; IMMUNOFLUORESCENCE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; RAT; START CODON; T LYMPHOCYTE;

ANIMALIA;

EID: 0242390383     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/154545703322460603     Document Type: Article

References (44)

1. ADLER, S.H., and TURKA, L.A. (2002). Immunotherapy as a means to induce transplantation tolerance. Curr. Opin. Immunol. 14, 660-665.
2. AROSA, F.A., and DE SOUSA, M. (1995). Iron differentially modulates the CD4-lck and CD8-lck complexes in resting peripheral blood T-lymphocytes. Cell. Immunol. 161, 138-142.
3. BOEVE, C.M., and DE LEY, M. (1994). Inhibition of human interferon-gamma expression by antisense oligodeoxynucleotide. J. Leukocyte Biol. 55, 169-174.
4. CABALLERO, F., PELEGRÍ, C., CASTELL, M., FRANCH, A., and CASTELLOTE, C. (1998). Kinetics of W3/25 anti-rat CD4 monoclonal antibody. Studies on optimal doses and time-related effects. Immunopharmacology 39, 83-91.
5. CAMMAROTA, G., SHELIE, A., TAKACS, B., DORAN, D.M., KNORR, R., BANNWARTH, W., GUARDIOLA, J., and SINIGAGLIA, F. (1992). Identification of a CD4 binding site on the β2 domain of HLA-DR molecules. Nature 356, 799-801.
6. CHU, C.Q., and LONDEI, M. (1996). Induction of Th2 cytokines and control of collagen-induced arthritis by non-depleting anti-CD4 Abs. J. Immunol. 157, 2685-2689.
7. CLARK, S.J., JEFFERIES, W.A., BARCLAY, W., GAGNON, J., and WILLIAMS, A.K. (1987). Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: Evidence for derivation from a structure with four immunoglobulin-related domains. Proc. Natl. Acad. Sci. USA 84, 1649-1653.
8. CROOKE, S.T. (1998). Molecular mechanisms of antisense drugs: RNase H. Antisense Nucleic Acid Drug Dev. 8, 133-134.
9. CROOKE, S.T. (1999). Molecular mechanisms of action of antisense drugs. Biochim. Biophys. Acta 1489, 31-44.
10. DARZYNKIEWICZ, Z., LI, X., and GONG, J. (1994). Assays of cell viability: Discrimination of cells dying by apoptosis. Methods Cell Biol. 41, 15-38.
11. HAREL-BELLAN, A., DURUM, S., MUEGGE, K., ABBAS, A.K., and FARRAR, W.L. (1988). Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones. J. Exp. Med. 168, 2309-2318.
12. ISAACS, J.D., MORGAN, A.W., and STRAND, V. (1999). Combination biologic therapy. Clin. Exp. Rheumatol. 17 (Suppl. 18), S121-S124.
13. JANEWAY, C.A.J. (1989). The role of CD4 in T-cell activation: Accessory molecule or co-receptor? Immunol. Today 10, 234-238.
14. JASON, J., and INGE, K.L. (2001). Modulation of CD8 and CD3 by HIV of HIV antigens. Scand. J. Immunol. 53, 259-267.
15. KEYSTONE, E. (2002). Treatments no longer in development for rheumatoid arthritis. Ann. Rheum. Dis. 61 (Suppl. II), ii43-ii45.
16. KRIEG, A.M. (1999). Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys. Acta 1489, 107-116.
17. LIANG, X., LU, L., ZHANG, H., VICKERS, T., FUNG, J.J., and QIAN, S. (2001). Phenotype and allostimulatory function of dendritic cells treated with antisense oligodeoxyribonucleotides targeting CD80 or CD86 mRNA. Transplant. Proc. 33, 235.
18. MAURI, C., CHU, C.C.Q., WOODROW, D., MORI, L., and LONDEI, M. (1997). Treatment of a newly established transgenic model of chronic arthritis with nondepleting anti-CD4 monoclonal antibody. J. Immunol. 159, 5032-5041.
19. McCALL, M.N. (1998). Repressible antisense inhibition in B lymphocytes. Biochim. Biophys. Acta 1397, 65-72.
20. MOTOYAMA, K., ARIMA, T., YU, S., LEHMANN, M., and FLYE, M.W. (2000). The kinetics of tolerance induction by non-depleting anti-CD4 monoclonal antibody (RIB 5/2) plus intravenous donor alloantigen administration. Transplantation 69, 285-293.
21. MOTTRAM, P.L., RAISANEN-SOKOLOWSKI, A., GLUSING-JENSEN, T., STEIN-OAKLEY, A.N., and RUSELL, M.E. (1998). Redefining peripheral tolerance in the BALB/c to CBA mouse cardiac allograft model. Vascular and cytokine analysis after transient CD4 T cell depletion. Transplantation 66, 1510-1518.
22. NEPOM, G.T. (2002). Therapy of autoimmune diseases: Clinical trials and new biological. Curr. Opin. Immunol. 14, 812-815.
23. high T cells. Clin. Exp. Immunol. 125,470-477.
24. PELEGRÍ, C., MORANTE, M.P., CASTELLOTE, C., CASTELL, M., and FRANCH, A. (1995). Administration of a nondepleting anti-CD4 monoclonal antibody (W3/25) prevents adjuvant arthritis, even upon rechallenge: Parallel administration of a depleting anti-CD8 monoclonal antibody (OX8) does not modify the effect of W3/25. Cell. Immunol. 165, 177-182.
25. PELEGRÍ, C., MORANTE, M.P., CASTELLOTE, C., FRANCH, A., and CASTELL, M. (1996). Treatment with an anti-CD4 monoclonal antibody strongly ameliorates established rat adjuvant arthritis. Clin. Exp. Immunol. 103, 273-278.
26. PELEGRÍ, C., VILAPLANA, J., CASTELLOTE, C., RABANAL, M., FRANCH, A., and CASTELL, M. (2003). Circadian rhythms in surface molecules of rat blood lymphocytes. Am. J. Physiol. Cell Physiol. 284, C67-C76.
27. PEYMAN, A., and UHLMANN, E. (1996). Minimally modified oligonucleotides. Combination of end-capping and pyrimidine protection. Biol. Chem. Hoppe-Seyler 377, 67-70.
28. PHILLIPS, M.I., and GYURKO, R. (1995). In vivo applications of antisense oligonucleotides for peptide research. Regul. Pept. 59, 131-141.
29. PORSTMANN, T., TERNYNCK, T., and AVRAMEAS, S. (1985). Quantitation of 5-bromo-2-deoxyuridine incorporation into DNA: An enzyme immunoassay for the assessment of the lymphoid cell proliferative response. J. Immunol. Methods 82, 169-179.
30. QIAN, S., WANG, Z., LI, W., CHEN, Z., ZHANG, H., VICKERS, T., FUNG, J.J., and LU, L. (2001). Administration of antisense oligodeoxyribonucleotides against mRNA of CD80 or CD86 prolongs survival of cardiac allografts by inhibition of CTL activity. Transplant. Proc. 33, 551.
31. RABANAL, M., FRANCH, A., NOÉ, V., CIUDAD, C.J., CASTELL, M., and CASTELLOTE, C. (2002). Inhibition of CD4 expression by antisense oligonucleotides in PMA-treated lymphocytes. Antisense Nucleic Acid Drug Dev. 12, 399-410.
32. ROBBINS, P.D., EVANS, C.H., and CHERNAJOVSKY, Y. (2003). Gene therapy for arthritis. Gene Ther. 10, 902-911.
33. SALGADO, J., GILABERT, A., CASTELL, M., CASTELLOTE, C., and QUERALT, J. (1988). ELISA for quantification of specific IgG and IgE antibodies to ovalbumin. Allergol. Immunopathol. 16, 95-98.
34. SANTIAGO, F.S., and KHACHIGIAN, L.M. (2001). Nucleic acid bases strategies as potential therapeutic tools: Mechanistic considerations and implications to restenosis. J. Mol. Med. 79, 695-706.
35. SCHULZE-KOOPS, H., DAVIS, L.S., HAVERTY, T.P., WACHOLTZ, M.C., and LIPSKY, P.E. (1998). Reduction of Th1 cell activity in the peripheral circulation of patients with rheumatoid arthritis after treatment with a non-depleting humanized monoclonal antibody to CD4. J. Rheumatol. 25, 2065-2076.
36. SEWELL, K.L., GEARY, R.S., BAKER, B.F., GLOVER, J.M., MANT, P.G., YU, R.Z., TAMI, J.A., and DORR, F.A. (2002). Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha. J. Pharmacol. Exp. Ther. 303, 1334-1343.
37. STEPKOWSKI, S.M., WANG, M.E., CONDON, T.P., CHENG-FLOURNOY, S., STECKER, K., GRAHAM, M., QU, X., TIAN, L., CHEN, W., KAHAN, B.D., and BENNETT, C.F. (1998). Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides. Transplant. 66, 699-707.
38. TAYLOR, M.F., PAULASKIS, J.D., WELLER, D.D., and KOBZIK, L. (1996). In vitro efficacy of morpholino-modified antisense oligomers directed tumor necrosis factor-α mRNA. J. Biol. Chem. 271, 17445-17452.
39. VAN ASSCHE, G., and RUTGEERTS, P. (2002). Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm. Bowel Dis. 8, 291-300.
40. VAN DEN BROEK, M.F., VAN DE LANGERIJT, L.G.M., VAN BRUGGEN, M.C.J., BILLINGHAM, M.E.J., and VAN DEN BERG, W.B. (1992). Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur. J. Immunol. 22, 57-61.
41. + cells in patients with rheumatoid arthritis. J. Autoimmun. 10, 87-97.
42. WANG, H., PRASAD, G., BUOLAMWINI, J.K., and ZHANG, R. (2001). Antisense anticancer oligonucleotide therapeutics. Curr. Cancer Drug Targets 1, 177-196.
43. YACYSHYN, B.R., BOWEN-YACYSHYN, M.B., JEWELL, L., TAMI, J.A., BENNETT, C.F., KISNER, D.L., and SHANAHAN, W.R., JR. (1998). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 114, 1133-1142.
44. YUN, S., SAWYER, G.J., ZHANG, X., GUSTAFSSON, K., and FABRE, J.W. (2000). Specific suppression of interleukin 2 biosynthesis by synthetic antisense oligodeoxynucleotides does not influence allograft rejection. Transplantation 69, 2586-2592.